{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:21:35Z","timestamp":1780446095071,"version":"3.54.1"},"reference-count":55,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T00:00:00Z","timestamp":1469577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Severe skin reactions may complicate combination antiretroviral therapy (cART). Nevirapine is known to be associated with severe skin reactions, but there are conflicting data on risk factors in African patients. We reviewed cases of severe skin reactions admitted to a tertiary hospital in Cape Town, South Africa. We identified associations with severe skin reactions in patients on cART.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We described severe skin reaction cases in patients taking cART admitted to Groote Schuur Hospital in Cape Town, South Africa, between 2006 and 2012. We included those patients who developed a severe skin reaction within 120\u2009days of cART initiation in a case\u2013control analysis. We identified control patients matched on date of cART initiation and primary care facility by linkage with the Western Cape electronic provincial HIV database. We conducted a conditional (fixed effects) logistic regression modelling.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 169 severe skin reactions in patients on cART. The most common presentations were Stevens Johnson syndrome\/toxic epidermal necrolysis (49%) and drug hypersensitivity syndrome (36%). One hundred forty\u2010one patients were female, of which 27 were pregnant. Median duration of hospitalization was 12\u2009days (interquartile range 8 to 19) and six patients died. We included 91 cases and 361 matched controls in the analysis. Severe skin reaction was associated with nevirapine exposure, adjusted odds ratio of 7.6 (95%CI 3.7 to 15.7) and with pregnancy, adjusted odds ratio 3.7 (95%CI 1.3 to 10.8) compared with men.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Severe skin reactions resulted in prolonged admission to hospital in this setting. We found that nevirapine use and pregnancy are independently associated with severe skin reaction. Copyright \u00a9 2016 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4067","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T04:42:40Z","timestamp":1469680960000},"page":"1313-1319","source":"Crossref","is-referenced-by-count":18,"title":["Severe antiretroviral\u2010associated skin reactions in South African patients: a case series and case\u2013control analysis"],"prefix":"10.1002","volume":"25","author":[{"given":"Annemie","family":"Stewart","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine University of Cape Town  Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rannakoe","family":"Lehloenya","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine University of Cape Town  Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Boulle","sequence":"additional","affiliation":[{"name":"School of Public Health and Family Medicine University of Cape Town  Cape Town South Africa"},{"name":"Health Impact Assessment Directorate, Department of Health Provincial Government of the Western Cape  Cape Town South Africa"},{"name":"Institute of Infectious Diseases and Molecular Medicine University of Cape Town  Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"de Waal","sequence":"additional","affiliation":[{"name":"School of Public Health and Family Medicine University of Cape Town  Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Maartens","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine University of Cape Town  Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine University of Cape Town  Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,7,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200501280-00011"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3233\/JRS-2011-0532"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318189a769"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-12-7"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318033ffa1"},{"issue":"1","key":"e_1_2_9_7_1","first-page":"22","article-title":"Cutaneous side effects of antiretroviral drugs","volume":"22","author":"Kane A","year":"2007","journal-title":"Mali M\u00e9dical"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2007.0093"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012617"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn292"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80105-7"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835f1db0"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03784.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.02.059"},{"key":"e_1_2_9_15_1","first-page":"203","article-title":"Severe cutaneous adverse reactions to drugs (SCAR): definitions, diagnostic criteria, genetic predisposition","volume":"27","author":"Roujeau J","year":"2009","journal-title":"Dermatologica Sin"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.7196\/SAMJ.5700"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1086\/324088"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200407010-00002"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000162334.12815.5b"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32831d0faf"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00513.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2010.00873.x"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832d3b54"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-003-0613-3"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874613601206010266"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.2174\/157016208783571946"},{"key":"e_1_2_9_27_1","unstructured":"RegiSCAR study group.International Registry of Severe Cutaneous Adverse Reactions (SCAR) to Drugs and Collection of Biological Samples Study Protocol.;2010."},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.1.18908"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/10629360600810434"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4067"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/00015550310002611"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200305010-00007"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31828011ca.WHO"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-188"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2007.00477.x"},{"issue":"7","key":"e_1_2_9_36_1","first-page":"839","article-title":"Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine","volume":"34","author":"Gangar M","year":"2000","journal-title":"Drug Interact React"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200108170-00018"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1258\/095646207782212289"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2007.00433.x"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00597.x"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200009290-00012"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000137372.18814.34"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1086\/382677"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15997-7"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1009231#SA1"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328351a521"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt287"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.7196\/SAMJ.6077"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31825c36fc"},{"key":"e_1_2_9_50_1","first-page":"29","article-title":"Maternal deaths due to adverse drug reactions to nevirapine\u2010containing HAART: new recommendations for ARV therapy in pregnancy in South Africa","volume":"22","author":"Moran NF","year":"2012","journal-title":"Obstet Gynaecol Forum"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmi008"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0733"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871528113666140717113358"},{"issue":"6","key":"e_1_2_9_54_1","first-page":"238","article-title":"Cutaneous adverse drug reactions","volume":"29","author":"Lehloenya R","year":"2011","journal-title":"Contin Med Educ"},{"key":"e_1_2_9_55_1","doi-asserted-by":"crossref","unstructured":"LinD LiW RiederM.Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV\/AIDS in patients with previous history of hypersensitivity to cotrimoxazole (Review). Cochran HIV\/AIDS Group;2009. doi:10.1002\/14651858.CD005646.pub2.","DOI":"10.1002\/14651858.CD005646.pub2"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2006.01.015"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4067","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T04:14:57Z","timestamp":1696392897000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,27]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1002\/pds.4067"],"URL":"https:\/\/doi.org\/10.1002\/pds.4067","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,27]]}}}